AL-amyloidosis with cardiac involvement. Diagnostic capabilities of non-invasive methods
Authors:
Open Access
- 15 April 2021
- journal article
- review article
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 93 (4) , 487-496
Abstract
There are presented the literature data and a description of the clinical course of the disease in isolated/predominant cardiac amyloidosis. Amyloid cardiomyopathy is the most common phenocopy of hypertrophic cardiomyopathy. The modern possibilities of non-invasive diagnostics using osteoscintigraphy for the differential diagnosis between amyloid cardiomyopathy caused by AL- and transthyretin amyloidosis are described in detail.Keywords
This publication has 30 references indexed in Scilit:
- 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathyEuropean Heart Journal, 2014
- 99m Tc-Pyrophosphate Scintigraphy for Differentiating Light-Chain Cardiac Amyloidosis From the Transthyretin-Related Familial and Senile Cardiac AmyloidosesCirculation: Cardiovascular Imaging, 2013
- Updates in Cardiac Amyloidosis: A ReviewJournal of the American Heart Association, 2012
- Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain MeasurementsJournal of Clinical Oncology, 2012
- Myocardial infarction with “clean coronaries” caused by amyloid light-chain AL amyloidosis: a case report and literature reviewAmyloid, 2011
- Amyloid diseases of the heart: assessment, diagnosis, and referralHeart, 2010
- Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) AmyloidosisJournal of Clinical Oncology, 2010
- Light-Chain (AL) AmyloidosisClinical Journal of the American Society of Nephrology, 2006
- The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosisBlood, 2006
- Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practiceArthritis & Rheumatism, 2006